Q1 Earnings Forecast for Exelixis Issued By Leerink Partnrs

Exelixis, Inc. (NASDAQ:EXEL) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Exelixis in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the biotechnology company will post earnings per share of $0.35 for the quarter. The consensus estimate for Exelixis’ current full-year earnings is $1.74 per share. Leerink Partnrs also issued estimates for Exelixis’ Q2 2025 earnings at $0.49 EPS, Q3 2025 earnings at $0.60 EPS and Q4 2025 earnings at $0.65 EPS.

Other equities analysts have also recently issued reports about the company. JMP Securities reaffirmed a “market outperform” rating and issued a $41.00 price target on shares of Exelixis in a research note on Thursday, January 23rd. Stephens reaffirmed an “equal weight” rating and issued a $29.00 price target on shares of Exelixis in a research note on Monday, January 27th. Bank of America cut Exelixis from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $35.00 to $39.00 in a research note on Tuesday, December 17th. Truist Financial lifted their price target on Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Finally, BMO Capital Markets cut Exelixis from an “outperform” rating to a “market perform” rating and lifted their price target for the stock from $36.00 to $40.00 in a research note on Friday, December 20th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.06.

Exelixis Price Performance

Shares of Exelixis stock opened at $33.48 on Friday. The business’s 50 day simple moving average is $34.39 and its two-hundred day simple moving average is $30.45. The stock has a market capitalization of $9.56 billion, a P/E ratio of 21.46, a price-to-earnings-growth ratio of 0.72 and a beta of 0.53. Exelixis has a one year low of $20.01 and a one year high of $37.59.

Insider Activity at Exelixis

In related news, EVP Jeffrey Hessekiel sold 60,000 shares of Exelixis stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the sale, the executive vice president now directly owns 486,059 shares in the company, valued at $17,823,783.53. The trade was a 10.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Patrick J. Haley sold 10,000 shares of the business’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $35.27, for a total value of $352,700.00. Following the completion of the sale, the executive vice president now directly owns 278,665 shares in the company, valued at $9,828,514.55. This trade represents a 3.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 111,588 shares of company stock worth $3,981,864 over the last ninety days. 2.85% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Exelixis

Several hedge funds have recently added to or reduced their stakes in EXEL. V Square Quantitative Management LLC bought a new stake in Exelixis in the third quarter worth $30,000. USA Financial Formulas bought a new stake in Exelixis in the fourth quarter worth $32,000. Principal Securities Inc. boosted its holdings in Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 373 shares in the last quarter. Kestra Investment Management LLC bought a new stake in Exelixis in the fourth quarter worth $39,000. Finally, Brooklyn Investment Group bought a new stake in Exelixis in the third quarter worth $42,000. 85.27% of the stock is owned by institutional investors.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.